



MEN

FIRST CANCER SITE
PROSTATEPROSTATE
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

PROSTATA
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	135708		143241		143241		135708		114414		44199		9567		135708	143241
Person-years ▶	547059		570207		23148		103980		301800		116756		24523		547059	570207
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
LL SITES, BUT SKIN AND PROSTATE	10956	0.93	13186	1.08	2230	4.90	2244	1.09	5758	0.90	2410	0.88	544	0.87	-1.55	1.62
HEAD AND NECK	396	0.79	416	0.80	20	0.93	68	0.71	229	0.83	86	0.82	13	0.62	-0.19	-0.18
ORAL CAVITY	81	0.69	84	0.69	3	0.61	9	0.40	52	0.80	17	0.68	3	0.58	-0.07	-0.07
PHARYNX	83	0.84	87	0.84	4	0.92	17	0.87	49	0.89	17	0.85	0	0.00	-0.03	-0.03
LARYNX	232	0.82	245	0.83	13	1.07	42	0.77	128	0.82	52	0.87	10	0.83	-0.09	-0.09
OESOPHAGUS	118	0.82	127	0.85	9	1.54	28	1.07	58	0.74	29	0.91	3	0.43	-0.05	-0.04
STOMACH	825	0.90	864	0.91	39	1.09	135	0.84	466	0.95	190	0.89	34	0.67	-0.16	-0.15
COLON RECTUM	2294	1.10	2389	1.10	95	1.21	403	1.13	1247	1.11	512	1.04	132	1.15	0.38	0.39
COLON	1600	1.10	1668	1.10	68	1.26	272	1.11	894	1.15	350	1.00	84	1.03	0.26	0.28
RECTUM	694	1.10	721	1.10	27	1.10	131	1.18	353	1.03	162	1.11	48	1.47	0.11	0.11
LIVER	368	0.63	385	0.63	17	0.74	72	0.69	174	0.55	106	0.80	16	0.55	-0.40	-0.39
GALLBLADDER	140	0.82	147	0.83	7	1.11	16	0.56	88	0.97	29	0.71	7	0.71	-0.05	-0.05
PANCREAS	395	0.96	410	0.96	15	0.97	85	1.21	192	0.87	96	0.99	22	0.96	-0.03	-0.03
LUNG	1871	0.74	2145	0.82	274	2.76	378	0.84	979	0.71	430	0.75	84	0.66	-1.20	-0.84
SKIN MELANOMA	251	1.31	273	1.38	22	3.08	52	1.59	126	1.22	60	1.34	13	1.27	0.11	0.13
MESOTHELIOMA	97	1.24	104	1.28	7	2.38	14	1.04	57	1.33	24	1.32	2	0.51	0.03	0.04
KAPOSI SARCOMA	38	1.23	44	1.37	6	5.08	6	1.12	19	1.15	12	1.66	1	0.57	0.01	0.02
SOFT TISSUE	56	1.15	58	1.15	2	1.08	8	0.95	30	1.15	15	1.31	3	1.12	0.01	0.01
BONE	13	1.13	14	1.17	1	2.08	5	2.33	5	0.80	3	1.18	0	0.00	0.00	0.00
BREAST	30	0.96	36	1.11	6	5.05	7	1.30	15	0.89	7	0.96	1	0.60	0.00	0.01
PROSTATE	2	0.00	6	0.00	4	0.03	0	0.00	1	0.00	1	0.00	0	0.00	-5.75	-5.72
TESTIS	3	0.32	6	0.61	3	7.43	1	0.56	1	0.19	1	0.50	0	0.00	-0.01	-0.01
KIDNEY AND RENAL PELVIS	543	1.25	646	1.43	103	6.12	227	2.96	217	0.92	84	0.84	15	0.68	0.20	0.34
BLADDER AND URINARY TRACT	1845	1.11	3296	1.90	1451	22.78	424	1.46	986	1.10	337	0.86	98	1.09	0.33	2.75
URINARY BLADDER	1782	1.12	3209	1.94	1427	23.42	410	1.48	958	1.12	322	0.87	92	1.08	0.35	2.73
URINARY TRACT	63	0.84	87	1.12	24	8.67	14	1.11	28	0.70	15	0.83	6	1.34	-0.02	0.02
BRAIN AND CENTRAL NERVOUS SYSTEM	132	0.89	138	0.89	6	1.00	30	1.10	58	0.71	35	1.06	9	1.29	-0.03	-0.03
THYROID	80	1.50	86	1.55	6	2.73	21	2.10	39	1.31	17	1.51	3	1.39	0.05	0.05
HODGKIN LYMPHOMA	17	0.75	24	1.02	7	7.39	6	1.41	9	0.73	2	0.41	0	0.00	-0.01	0.00
NON-HODGKIN LYMPHOMA	400	1.00	429	1.03	29	1.88	85	1.21	200	0.92	89	0.96	26	1.24	0.00	0.02
MYELOMA	198	0.99	211	1.02	13	1.72	37	1.08	115	1.08	37	0.78	9	0.81	0.00	0.01
LEUKAEMIAS	339	0.99	376	1.06	37	2.82	51	0.86	179	0.98	89	1.11	20	1.06	0.00	0.04
LYMPHOID LEUKAEMIAS	141	0.89	170	1.03	29	4.62	25	0.88	72	0.84	33	0.90	11	1.29	-0.03	0.01
MYELOID LEUKAEMIAS	182	1.16	188	1.15	6	1.02	23	0.86	100	1.19	50	1.33	9	1.01	0.05	0.04
OTHER LEUKAEMIAS	16	0.65	18	0.70	2	2.06	3	0.69	7	0.54	6	1.03	0	0.00	-0.02	-0.01
OTHER AND ILL DEFINED SITES	507	0.63	562	0.68	55	1.86	85	0.63	269	0.63	120	0.62	33	0.69	-0.54	-0.47

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio